{"id":57731,"date":"2026-02-24T17:51:33","date_gmt":"2026-02-24T09:51:33","guid":{"rendered":"https:\/\/flcube.com\/?p=57731"},"modified":"2026-02-24T17:51:34","modified_gmt":"2026-02-24T09:51:34","slug":"cspc-pharmaceutical-wins-nmpa-approval-for-phase-ii-study-of-sys6023-her3-adc-in-metastatic-breast-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57731","title":{"rendered":"CSPC Pharmaceutical Wins NMPA Approval for Phase II Study of SYS6023 HER3 ADC in Metastatic Breast Cancer"},"content":{"rendered":"\n<p><strong>CSPC Pharmaceutical Group Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/1093:HKG\">HKG:\u202f1093<\/a>)<\/strong> announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has granted approval to initiate a <strong>Phase II clinical study<\/strong> for <strong>SYS6023<\/strong>, a <strong>Category\u202f1 biologic HER3\u2011targeting antibody\u2011drug conjugate (ADC)<\/strong>. The study will evaluate SYS6023 in <strong>combination therapy<\/strong> for patients with <strong>unresectable locally advanced or metastatic breast cancer<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>CSPC Pharmaceutical Group Ltd (HKG:\u202f1093)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>SYS6023 (HER3\u2011targeting ADC)<\/td><\/tr><tr><td><strong>Regulatory Action<\/strong><\/td><td>NMPA approval for Phase II clinical study<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Category\u202f1 innovative biologic<\/td><\/tr><tr><td><strong>Study Design<\/strong><\/td><td>Phase II combination therapy<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Unresectable locally advanced or metastatic breast cancer<\/td><\/tr><tr><td><strong>Payload<\/strong><\/td><td>In\u2011house developed topoisomerase I inhibitor<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-sys6023\">Drug Profile \u2013 SYS6023<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target:<\/strong> <strong>HER3 (human epidermal growth factor receptor 3)<\/strong> \u2013 emerging target in breast cancer and other solid tumors<\/li>\n\n\n\n<li><strong>Class:<\/strong> Antibody\u2011drug conjugate (ADC)<\/li>\n\n\n\n<li><strong>Payload:<\/strong> <strong>Topoisomerase I inhibitor<\/strong> \u2013 developed in\u2011house by CSPC<\/li>\n\n\n\n<li><strong>Mechanism of Action:<\/strong><\/li>\n<\/ul>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Binds to HER3 receptors on tumor cell surface<\/li>\n\n\n\n<li>Internalization via endocytosis<\/li>\n\n\n\n<li>Intracellular toxin release to induce cancer cell death<\/li>\n<\/ol>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Differentiation:<\/strong> Payload is <strong>not a substrate for efflux pumps<\/strong>, potentially avoiding efflux\u2011mediated resistance associated with DXd\u2011class ADCs<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HER3 Target Validation:<\/strong> HER3 is frequently overexpressed in breast cancer and associated with resistance to HER2\u2011targeted therapies, making it an attractive target for next\u2011generation ADCs.<\/li>\n\n\n\n<li><strong>Resistance Advantage:<\/strong> The <strong>non\u2011substrate payload design<\/strong> may confer superior activity in tumors with acquired resistance mechanisms, differentiating SYS6023 from competitors using DXd\u2011based payloads.<\/li>\n\n\n\n<li><strong>Pipeline Expansion:<\/strong> This approval advances CSPC&#8217;s <strong>oncology biologics portfolio<\/strong>, complementing existing small\u2011molecule and biologic assets in the company&#8217;s diversified pipeline.<\/li>\n\n\n\n<li><strong>Combination Strategy:<\/strong> Phase II evaluation in <strong>combination therapy<\/strong> aligns with current treatment paradigms for metastatic breast cancer, where multi\u2011agent regimens are standard of care.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Breast Cancer Burden:<\/strong> Metastatic breast cancer remains a leading cause of cancer mortality globally, with significant unmet need for novel therapies in the post\u2011CDK4\/6 inhibitor and post\u2011HER2\u2011targeted settings.<\/li>\n\n\n\n<li><strong>ADC Competitive Landscape:<\/strong> The HER3\u2011ADC space includes Daiichi Sankyo\/AstraZeneca&#8217;s <strong>patritumab deruxtecan<\/strong>, setting a high efficacy benchmark. CSPC&#8217;s <strong>efflux\u2011resistant payload<\/strong> may offer a mechanistic edge in resistant populations.<\/li>\n\n\n\n<li><strong>China Regulatory Momentum:<\/strong> NMPA&#8217;s rapid approval for Phase II initiation reflects China&#8217;s supportive environment for <strong>Category\u202f1 innovative biologics<\/strong> and ADC development.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, efficacy expectations, and commercial potential for SYS6023. Actual results may differ due to risks including clinical trial outcomes, competitive dynamics, and manufacturing challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/\u65b0\u8bfa\u5a01\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8SYS6023\u6297\u4f53\u5076\u8054\u836f\u7269\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u65b0\u8bfa\u5a01\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8SYS6023\u6297\u4f53\u5076\u8054\u836f\u7269\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-1cbaff52-4106-4a1d-9a3a-71a9cda7eb77\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/\u65b0\u8bfa\u5a01\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8SYS6023\u6297\u4f53\u5076\u8054\u836f\u7269\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\">\u65b0\u8bfa\u5a01\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8SYS6023\u6297\u4f53\u5076\u8054\u836f\u7269\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/\u65b0\u8bfa\u5a01\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8SYS6023\u6297\u4f53\u5076\u8054\u836f\u7269\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-1cbaff52-4106-4a1d-9a3a-71a9cda7eb77\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CSPC Pharmaceutical Group Ltd (HKG:\u202f1093) announced that China&#8217;s National Medical Products Administration (NMPA) has granted&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,62,171,855],"class_list":["post-57731","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-clinical-trial-approval-initiation","tag-cspc-pharmaceutical","tag-hkg-1093"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CSPC Pharmaceutical Wins NMPA Approval for Phase II Study of SYS6023 HER3 ADC in Metastatic Breast Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CSPC Pharmaceutical Group Ltd (HKG:\u202f1093) announced that China&#039;s National Medical Products Administration (NMPA) has granted approval to initiate a Phase II clinical study for SYS6023, a Category\u202f1 biologic HER3\u2011targeting antibody\u2011drug conjugate (ADC). The study will evaluate SYS6023 in combination therapy for patients with unresectable locally advanced or metastatic breast cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=57731\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CSPC Pharmaceutical Wins NMPA Approval for Phase II Study of SYS6023 HER3 ADC in Metastatic Breast Cancer\" \/>\n<meta property=\"og:description\" content=\"CSPC Pharmaceutical Group Ltd (HKG:\u202f1093) announced that China&#039;s National Medical Products Administration (NMPA) has granted approval to initiate a Phase II clinical study for SYS6023, a Category\u202f1 biologic HER3\u2011targeting antibody\u2011drug conjugate (ADC). The study will evaluate SYS6023 in combination therapy for patients with unresectable locally advanced or metastatic breast cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=57731\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-24T09:51:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-24T09:51:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57731#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57731\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CSPC Pharmaceutical Wins NMPA Approval for Phase II Study of SYS6023 HER3 ADC in Metastatic Breast Cancer\",\"datePublished\":\"2026-02-24T09:51:33+00:00\",\"dateModified\":\"2026-02-24T09:51:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57731\"},\"wordCount\":426,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Clinical trial approval \\\/ initiation\",\"CSPC Pharmaceutical\",\"HKG: 1093\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57731#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57731\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=57731\",\"name\":\"CSPC Pharmaceutical Wins NMPA Approval for Phase II Study of SYS6023 HER3 ADC in Metastatic Breast Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-24T09:51:33+00:00\",\"dateModified\":\"2026-02-24T09:51:34+00:00\",\"description\":\"CSPC Pharmaceutical Group Ltd (HKG:\u202f1093) announced that China's National Medical Products Administration (NMPA) has granted approval to initiate a Phase II clinical study for SYS6023, a Category\u202f1 biologic HER3\u2011targeting antibody\u2011drug conjugate (ADC). The study will evaluate SYS6023 in combination therapy for patients with unresectable locally advanced or metastatic breast cancer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57731#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57731\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57731#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CSPC Pharmaceutical Wins NMPA Approval for Phase II Study of SYS6023 HER3 ADC in Metastatic Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CSPC Pharmaceutical Wins NMPA Approval for Phase II Study of SYS6023 HER3 ADC in Metastatic Breast Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"CSPC Pharmaceutical Group Ltd (HKG:\u202f1093) announced that China's National Medical Products Administration (NMPA) has granted approval to initiate a Phase II clinical study for SYS6023, a Category\u202f1 biologic HER3\u2011targeting antibody\u2011drug conjugate (ADC). The study will evaluate SYS6023 in combination therapy for patients with unresectable locally advanced or metastatic breast cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=57731","og_locale":"en_US","og_type":"article","og_title":"CSPC Pharmaceutical Wins NMPA Approval for Phase II Study of SYS6023 HER3 ADC in Metastatic Breast Cancer","og_description":"CSPC Pharmaceutical Group Ltd (HKG:\u202f1093) announced that China's National Medical Products Administration (NMPA) has granted approval to initiate a Phase II clinical study for SYS6023, a Category\u202f1 biologic HER3\u2011targeting antibody\u2011drug conjugate (ADC). The study will evaluate SYS6023 in combination therapy for patients with unresectable locally advanced or metastatic breast cancer.","og_url":"https:\/\/flcube.com\/?p=57731","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-24T09:51:33+00:00","article_modified_time":"2026-02-24T09:51:34+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=57731#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=57731"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CSPC Pharmaceutical Wins NMPA Approval for Phase II Study of SYS6023 HER3 ADC in Metastatic Breast Cancer","datePublished":"2026-02-24T09:51:33+00:00","dateModified":"2026-02-24T09:51:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=57731"},"wordCount":426,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Clinical trial approval \/ initiation","CSPC Pharmaceutical","HKG: 1093"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=57731#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=57731","url":"https:\/\/flcube.com\/?p=57731","name":"CSPC Pharmaceutical Wins NMPA Approval for Phase II Study of SYS6023 HER3 ADC in Metastatic Breast Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-24T09:51:33+00:00","dateModified":"2026-02-24T09:51:34+00:00","description":"CSPC Pharmaceutical Group Ltd (HKG:\u202f1093) announced that China's National Medical Products Administration (NMPA) has granted approval to initiate a Phase II clinical study for SYS6023, a Category\u202f1 biologic HER3\u2011targeting antibody\u2011drug conjugate (ADC). The study will evaluate SYS6023 in combination therapy for patients with unresectable locally advanced or metastatic breast cancer.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=57731#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=57731"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=57731#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CSPC Pharmaceutical Wins NMPA Approval for Phase II Study of SYS6023 HER3 ADC in Metastatic Breast Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57731","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57731"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57731\/revisions"}],"predecessor-version":[{"id":57735,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57731\/revisions\/57735"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57731"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57731"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57731"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}